US Stock Activity: Summit Therapeutics surged on October 19 due to phase II kidney cancer trial and cooperation with Akeso

Bitget异动解读2026/10/19 15:30

Show original

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Summit Therapeutics Soars on October 19: Analysis

Keywords: Renal cancer Phase II trial, Akeso collaboration

1. On October 19, Summit announced the initiation and opening of a multi-regional randomized Phase II clinical study in partnership with Akeso, aiming to enroll approximately 100 clear cell renal cancer patients who have not previously received systemic therapy for advanced disease. The trial centers are located in the United States and China.

2. The trial protocol released on October 19 evaluates ivonescimab as monotherapy, in combination with cadonilimab or ipilimumab, and uses nivolumab combined with ipilimumab as the standard treatment control arm. Ivonescimab is the company's PD-1/VEGF bispecific antibody in development.

(Disclaimer: This content is generated by AI technology summarizing publicly available information and is for reference only. It does not constitute investment advice.)

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

If the agreement is implemented, the total scale of cooperation between the two parties will reach $90 billions. The relevant negotiations involve the second building of the Monarch data center campus, which provides 460MW of computing power and adopts NVIDIA’s latest generation Vera Rubin chips. In addition, Anthropic has also obtained the priority negotiation rights for the third building in the Monarch campus plan.

华尔街见闻•2026/10/19 20:51